Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.

Gordeuk VR, Campbell A, Rana S, Nouraie M, Niu X, Minniti CP, Sable C, Darbari D, Dham N, Onyekwere O, Ammosova T, Nekhai S, Kato GJ, Gladwin MT, Castro OL.

Blood. 2009 Nov 19;114(21):4639-44. doi: 10.1182/blood-2009-04-218040. Epub 2009 Sep 1.

2.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

3.

Treatment of sickle cell anemia with hydroxyurea and erythropoietin.

Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF.

N Engl J Med. 1990 Aug 9;323(6):366-72.

4.

Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia.

Gordeuk VR, Minniti CP, Nouraie M, Campbell AD, Rana SR, Luchtman-Jones L, Sable C, Dham N, Ensing G, Prchal JT, Kato GJ, Gladwin MT, Castro OL.

Haematologica. 2011 Jan;96(1):33-40. doi: 10.3324/haematol.2010.030767. Epub 2010 Sep 30.

5.

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP.

N Engl J Med. 2004 Feb 26;350(9):886-95.

6.

Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.

Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.

N Engl J Med. 1993 Jan 14;328(2):73-80.

7.

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Blood Cells Mol Dis. 2000 Oct;26(5):453-66.

PMID:
11112383
8.

Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.

Blood. 2002 Jan 1;99(1):10-4.

9.

Hydroxyurea and erythropoietin therapy in sickle cell anemia.

Goldberg MA, Brugnara C, Dover GJ, Schapira L, Lacroix L, Bunn HF.

Semin Oncol. 1992 Jun;19(3 Suppl 9):74-81.

PMID:
1379376
10.

Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease.

Elbarbary NS, Ismail EA, Roushdy A, Fahmy E.

Blood Cells Mol Dis. 2016 Mar;57:1-7. doi: 10.1016/j.bcmd.2015.11.001. Epub 2015 Nov 10.

PMID:
26852648
11.

Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.

Fitzhugh CD, Hsieh MM, Allen D, Coles WA, Seamon C, Ring M, Zhao X, Minniti CP, Rodgers GP, Schechter AN, Tisdale JF, Taylor JG 6th.

PLoS One. 2015 Nov 17;10(11):e0141706. doi: 10.1371/journal.pone.0141706. eCollection 2015.

12.

Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom.

Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JG 6th, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR; Walk-PHASST Investigators.

Circulation. 2011 Sep 27;124(13):1452-60. doi: 10.1161/CIRCULATIONAHA.111.032920. Epub 2011 Sep 6.

13.

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.

Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S.

PLoS One. 2013;8(2):e55709. doi: 10.1371/journal.pone.0055709. Epub 2013 Feb 7.

14.

Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.

Al-Nood HA, Al-Khawlani MM, Al-Akwa A.

Hemoglobin. 2011;35(1):13-21. doi: 10.3109/03630269.2011.551748.

PMID:
21250877
15.

Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients.

Teixeira SM, Cortellazzi LC, Grotto HZ.

Braz J Med Biol Res. 2003 Oct;36(10):1289-92. Epub 2003 Sep 16.

16.

Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.

Fung EB, Barden EM, Kawchak DA, Zemel BS, Ohene-Frempong K, Stallings VA.

J Pediatr Hematol Oncol. 2001 Dec;23(9):604-8.

PMID:
11902305
17.

[From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].

Nkashama GM, Wakamb GK, Mulangu AM, Nkashama GM, Kupa BK, Numbi OL.

Pan Afr Med J. 2015 Jun 15;21:124. doi: 10.11604/pamj.2015.21.124.5784. eCollection 2015. Review. French. No abstract available.

18.

Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation.

Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, Onyekwere O, Nouraie M, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR.

Haematologica. 2009 Mar;94(3):340-7. doi: 10.3324/haematol.13812. Epub 2009 Feb 11.

19.
20.

Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?

Segel GB, Simon W, Lichtman MA.

Pediatr Blood Cancer. 2011 Jul 15;57(1):8-9. doi: 10.1002/pbc.23128. Epub 2011 Apr 7. No abstract available.

PMID:
21480473

Supplemental Content

Support Center